Lexicon Pharmaceuticals, Inc. (LXRX)
USD 0.68
(-7.76%)
USD 0.68
(-7.76%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.2 Million | 139 Thousand | 298 Thousand | 23.99 Million | 322.07 Million | 63.2 Million |
| Cost of Revenue | 85 Thousand | 427 Thousand | 55.04 Million | 1.92 Million | 3.23 Million | 2.49 Million |
| Gross Profit | 1.11 Million | -288 Thousand | -54.74 Million | 22.06 Million | 318.84 Million | 60.71 Million |
| Operating Expenses | 172.86 Million | 100.89 Million | 87.38 Million | 200.85 Million | 148.75 Million | 163.99 Million |
| Selling, General and Administrative Expenses | 113.98 Million | 48.08 Million | 32.34 Million | 47.23 Million | 56.83 Million | 63.75 Million |
| Research and Development Expenses | 58.88 Million | 52.81 Million | 55.04 Million | 153.62 Million | 91.92 Million | 100.24 Million |
| Other Expenses | - | - | - | 1.6 Million | 28.63 Million | - |
| Cost and Expenses | 172.95 Million | 100.89 Million | 87.38 Million | 202.78 Million | 151.99 Million | 166.48 Million |
| Operating Income | -171.75 Million | -100.76 Million | -87.09 Million | -178.78 Million | 141.44 Million | -103.27 Million |
| Interest Expense | 13.1 Million | 2.78 Million | 802 Thousand | 14.54 Million | 20.67 Million | 20.77 Million |
| Income Tax Expense | - | 1.18 Million | 510 Thousand | 11.61 Million | -6.01 Million | 3.5 Million |
| Earnings before Tax | -177.11 Million | -101.94 Million | -87.75 Million | -58.57 Million | 124.11 Million | -120.54 Million |
| Net Income | -177.11 Million | -103.12 Million | -88.26 Million | -70.18 Million | 130.13 Million | -120.54 Million |
| Earnings Per Share Basic | -0.80 | -0.62 | -0.61 | -0.63 | 1.23 | -1.14 |
| Earnings Per Share Diluted | -0.80 | -0.62 | -0.61 | -0.63 | 1.11 | -1.14 |
| Weighted Average Shares Outstanding | 221.13 Million | 165.73 Million | 145.65 Million | 110.84 Million | 106.21 Million | 105.74 Million |
| Weighted Average Shares Outstanding (Diluted) | 221.13 Million | 165.73 Million | 145.65 Million | 110.84 Million | 116.74 Million | 105.83 Million |
| Gross Margin | 0.93 | -2.07 | -183.72 | 0.92 | 0.99 | 0.96 |
| EBIT Margin | -135.77 | -713.41 | -291.80 | -7.34 | 0.54 | -1.58 |
| Profit Margin | -147.11 | -741.93 | -296.20 | -2.92 | 0.40 | -1.91 |
| EBITDA | -163.46 Million | -98.73 Million | -86.66 Million | -41.09 Million | 173.73 Million | -96.08 Million |
| Earnings Before Tax Margin | -142.65 | -724.89 | -292.25 | -7.45 | 0.44 | -1.63 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 1.64 Million | 1.13 Million | 702 Thousand | 1.2 Million | 162 Thousand | 317 Thousand |
| Cost of Revenue | 305 Thousand | 175 Thousand | 217 Thousand | 639 Thousand | 7000.00 | 8000.00 |
| Gross Profit | 1.34 Million | 955 Thousand | 485 Thousand | 565 Thousand | 155 Thousand | 309 Thousand |
| Operating Expenses | 56.69 Million | 46.28 Million | 47.22 Million | 172.31 Million | 49.78 Million | 44.54 Million |
| Selling, General and Administrative Expenses | 39.19 Million | 32.06 Million | 32.6 Million | - | 32.22 Million | 30 Million |
| Research and Development Expenses | 17.5 Million | 14.22 Million | 14.61 Million | - | 17.55 Million | 14.54 Million |
| Other Expenses | -17.64 Million | - | 112 Thousand | - | - | - |
| Cost and Expenses | 57 Million | 46.46 Million | 47.43 Million | 172.95 Million | 49.79 Million | 44.55 Million |
| Operating Income | -55.35 Million | -45.33 Million | -46.73 Million | -171.75 Million | -49.63 Million | -44.24 Million |
| Interest Expense | 2.21 Million | 4.94 Million | 5.42 Million | 13.1 Million | 3.89 Million | 1.96 Million |
| Income Tax Expense | - | 100.72 Thousand | -2.97 Million | 386.1 Thousand | 2.85 Million | 1.15 Million |
| Earnings before Tax | -53.42 Million | -48.39 Million | -48.24 Million | -177.11 Million | -50.52 Million | -44.9 Million |
| Net Income | -53.42 Million | -48.39 Million | -48.24 Million | -177.11 Million | -50.52 Million | -44.9 Million |
| Earnings Per Share Basic | -0.17 | -0.20 | -0.20 | - | -0.21 | -0.22 |
| Earnings Per Share Diluted | -0.17 | -0.20 | -0.20 | - | -0.21 | -0.22 |
| Weighted Average Shares Outstanding | 310.83 Million | 245.39 Million | 244.92 Million | 221.13 Million | 244.92 Million | 204.78 Million |
| Weighted Average Shares Outstanding (Diluted) | 310.83 Million | 245.39 Million | 244.92 Million | 221.13 Million | 244.92 Million | 204.78 Million |
| Gross Margin | 0.81 | 0.85 | 0.69 | 0.47 | 0.96 | 0.97 |
| EBIT Margin | -33.52 | -39.99 | -66.37 | - | -287.81 | -135.47 |
| Profit Margin | -32.44 | -42.83 | -68.72 | -147.11 | -311.88 | -141.65 |
| EBITDA | -55.21 Million | -45.18 Million | -46.59 Million | - | -46.62 Million | -42.94 Million |
| Earnings Before Tax Margin | -33.61 | -40.12 | -66.58 | -142.65 | -306.36 | -139.56 |
NTBL
QLT
GENUSPRIME
0512
SMIN
2331